A Phase 2 interventional study of AFX3772 and Prevnar 13 in Pneumonia, Bacterial, Pneumococcal Infections and Pneumonia, Pneumococcal, sponsored by GlaxoSmithKline. Completed at 52 sites in 2 countries. Open to participants aged 42 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 2, and was the 8th registered.
44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.
Browse Pneumonia, Pneumococcal studies →None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →
Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 42 Days to 90 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 388 is close to the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.
Median enrollment 431 across the 11 interventional studies, 782 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 8 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 1 study filed under Pneumonia, Pneumococcal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV20).
Part 1 is the dose-escalation lead-in portion of the study, in which infants at each dose level are randomized 3:1 in sequential cohorts to receive increasing doses of AFX3772 or PCV13.
In Part 2, infants are randomized to receive either one of two dose levels of AFX3772 or PCV20.
On 31 October 2024, the study was placed on partial clinical hold by the U.S. Food and Drug Administration. The hold was not related to safety concerns in participants who had already received the study vaccines. As a result, enrollment was paused and no further doses of the investigational pneumococcal vaccine were administered. Participants who were already enrolled transitioned to the standard of care pneumococcal vaccine to complete their scheduled visits through post-dose 3 and subsequently completed study follow-up.
44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.
This study's enrollment of 388 is close to the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.
Browse Pneumonia, Pneumococcal studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Pneumonia, Pneumococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia, Bacterial. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant has a known or suspected immunodeficiency (including disease) or other conditions associated with that may require immunosuppressive drugs including but not limited to infection, or organ or bone marrow transplant.
a. In addition, the participant's biological mother has known HIV infection or known to be surface antigen positive.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AFX3772 1 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.
Biological: AFX3772 · Biological: Prevnar 13
AFX3772 2 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.
Biological: AFX3772 · Biological: Prevnar 13
AFX3772 5 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.
Biological: AFX3772 · Biological: Prevnar 13
PCV13 was administered at 2, 4, and 6 months of age.
Biological: Prevnar 13
AFX3772 2 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV20 as standard of care.
Biological: AFX3772 · Biological: Prevnar 20
FX3772 5 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV20 as standard of care.
Biological: AFX3772 · Biological: Prevnar 20
PCV20 was administered at 2, 4, and 6 months of age.
Biological: Prevnar 20
AFX3772 administered intramuscularly.
PCV13 administered intramuscularly.
Also known as: PCV13
PCV 20 administered intramuscularly.
Also known as: PCV20
Number of Participants Reporting Any Solicited Injection Site Adverse Events (AEs) After First Dose
The assessed solicited injection site events were pain/tenderness, redness/erythema and swelling/induration. Any = occurrence of the event regardless of the intensity grade.
Time frame: Day 1 to Day 7 post dose 1
Number of Participants Reporting Any Solicited Injection Site AEs After Second Dose
Time frame: Day 1 to Day 7 post dose 2
Number of Participants Reporting Any Solicited Injection Site AEs After Third Dose
Time frame: Day 1 to Day 7 post dose 3
Number of Participants Reporting Any Solicited Systemic Events After First Dose
The assessed solicited systemic events are irritability, fever, appetite loss, increased sleep, and decrease in sleep. Any = occurrence of the event regardless of the intensity grade.
Time frame: Day 1 to Day 7 post dose 1
Number of Participants Reporting Any Solicited Systemic Events After Second Dose
Time frame: Day 1 to Day 7 post dose 2
Number of Participants Reporting Any Solicited Systemic Events After Third Dose
Time frame: Day 1 to Day 7 post dose 3
Number of Participants Reporting Any Unsolicited AEs
An unsolicited AE was defined as any adverse event that was not actively solicited through the participant eDiary and was reported by the participant's legally authorized representative (LAR) or identified by site personnel. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the event regardless of the intensity grade.
Time frame: Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)
Number of Participants Reporting Any Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. Medical or scientific judgment will be exercised by the investigator in deciding whether SAE reporting is appropriate in other situations such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
Time frame: Day 1 through 6 months post dose 3
Proportion of Participants With a Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentration of >= 0.35 μg/mL
Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.
Time frame: 30 days post-dose 2 and 3
Geometric Mean Concentration (GMC) for Serotype-specific IgG
Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.
Time frame: 30 days post-dose 2 and 3
A total of 388 participants were enrolled in the study, including 130 in Part 1 and 258 in Part 2. Of these, 380 participants were randomized, and 376 participants received at least 1 dose of study vaccination.
| Milestone | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Started | 31 | 32 | 31 | 30 | 84 | 86 | 86 |
| Safety set | 30 | 32 | 30 | 29 | 83 | 86 | 86 |
| Completed | 23 | 24 | 27 | 23 | 55 | 72 | 65 |
| Not completed | 8 | 8 | 4 | 7 | 29 | 14 | 21 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 | 0 | 5 | 13 | 9 | 10 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 2 | 12 | 1 | 4 |
| Withdrew: Mis-randomization and not treated | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation affecting efficacy and/or safety | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Rescue medication | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Withdrew: Not, pre-specified | 2 | 4 | 3 | 0 | 0 | 1 | 3 |
The assessed solicited injection site events were pain/tenderness, redness/erythema and swelling/induration. Any = occurrence of the event regardless of the intensity grade.
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Tenderness | 16 | 15 | 11 | 17 | 38 | 36 | 34 |
| Erythema | 9 | 5 | 4 | 12 | 25 | 17 | 23 |
| Swelling | 4 | 2 | 6 | 7 | 22 | 16 | 18 |
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Tenderness | 18 | 15 | 4 | 11 | 18 | 11 | 14 |
| Erythema | 5 | 3 | 4 | 4 | 9 | 6 | 4 |
| Swelling | 2 | 2 | 3 | 4 | 7 | 4 | 5 |
Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.
Results for this outcome have not been posted.
Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.
Results for this outcome have not been posted.
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Tenderness | 15 | 3 | 0 | 9 | 10 | 4 | 4 |
| Erythema | 3 | 1 | 0 | 3 | 7 | 0 | 3 |
| Swelling | 2 | 0 | 0 | 3 | 5 | 0 | 1 |
The assessed solicited systemic events are irritability, fever, appetite loss, increased sleep, and decrease in sleep. Any = occurrence of the event regardless of the intensity grade.
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Irritability | 27 | 21 | 23 | 24 | 54 | 58 | 51 |
| Appetite Loss | 9 | 6 | 7 | 10 | 24 | 17 | 22 |
| Increased Sleep | 17 | 20 | 16 | 20 | 33 | 42 | 35 |
| Decrease in Sleep | 13 | 9 | 7 | 11 | 31 | 26 | 19 |
| Fever | 1 | 1 | 3 | 1 | 2 | 6 | 5 |
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Irritability | 25 | 21 | 4 | 14 | 25 | 19 | 19 |
| Appetite Loss | 9 | 6 | 0 | 6 | 10 | 5 | 8 |
| Increased Sleep | 18 | 14 | 3 | 9 | 12 | 14 | 14 |
| Decrease in Sleep | 15 | 9 | 2 | 10 | 11 | 11 | 11 |
| Fever | 1 | 1 | 0 | 1 | 1 | 2 | 3 |
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Irritability | 20 | 9 | 0 | 14 | 16 | 4 | 8 |
| Appetite Loss | 11 | 3 | 0 | 6 | 7 | 0 | 3 |
| Increased Sleep | 10 | 5 | 0 | 8 | 11 | 4 | 7 |
| Decrease in Sleep | 15 | 3 | 0 | 6 | 11 | 2 | 4 |
| Fever | 2 | 0 | 0 | 0 | 2 | 2 | 2 |
An unsolicited AE was defined as any adverse event that was not actively solicited through the participant eDiary and was reported by the participant's legally authorized representative (LAR) or identified by site personnel. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the event regardless of the intensity grade.
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Within 30 days, Post Dose 1 | 5 | 6 | 10 | 8 | 18 | 19 | 12 |
| Within 30 days, Post Dose 2 | 12 | 8 | 11 | 8 | 21 | 23 | 31 |
| Within 30 days, Post Dose 3 | 7 | 4 | 6 | 7 | 14 | 25 | 22 |
An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. Medical or scientific judgment will be exercised by the investigator in deciding whether SAE reporting is appropriate in other situations such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
| Participants | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Any Serious Adverse Events (SAEs) | 3 | 1 | 2 | 2 | 7 | 6 | 1 |
Collected over Solicited AEs: Day 1 - Day 7 post each vaccination, Unsolicited AEs: Day 1 - Day 30 post each vaccination. All-Cause mortality, SAEs: Day 1 through 6 months post dose 3. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: AFX3772 1 µg | 0/30 (0%) | 3/30 (10%) | 30/30 (100%) |
| Part 1: AFX3772 2 µg | 0/32 (0%) | 1/32 (3.1%) | 30/32 (93.8%) |
| Part 1: AFX3772 5 µg | 0/30 (0%) | 2/30 (6.7%) | 28/30 (93.3%) |
| Part 1 Comparator: PCV13 | 0/29 (0%) | 2/29 (6.9%) | 29/29 (100%) |
| Part 2: AFX3772 2 µg | 1/83 (1.2%) | 7/83 (8.4%) | 74/83 (89.2%) |
| Part 2: AFX3772 5 µg | 0/86 (0%) | 6/86 (7%) | 77/86 (89.5%) |
| Part 2 Comparator: PCV20 | 0/86 (0%) | 1/86 (1.2%) | 78/86 (90.7%) |
| Event | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| BronchiolitisInfections and infestations | 1/30 | 0/32 | 0/30 | 1/29 | 2/83 | 2/86 | 0/86 |
| StereotypyPsychiatric disorders | 0/30 | 0/32 | 0/30 | 1/29 | 0/83 | 0/86 | 0/86 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 1/30 | 1/32 | 0/30 | 0/29 | 2/83 | 2/86 | 1/86 |
| Escherichia urinary tract infectionInfections and infestations | 0/30 | 0/32 | 1/30 | 0/29 | 0/83 | 0/86 | 0/86 |
| Gastroenteritis viralInfections and infestations | 1/30 | 0/32 | 0/30 | 0/29 | 0/83 | 0/86 | 0/86 |
| HaematemesisGastrointestinal disorders | 1/30 | 0/32 | 0/30 | 0/29 | 0/83 | 0/86 | 0/86 |
| Failure to thriveMetabolism and nutrition disorders | 0/30 | 0/32 | 1/30 | 0/29 | 0/83 | 0/86 | 0/86 |
| CellulitisInfections and infestations | 0/30 | 0/32 | 0/30 | 0/29 | 1/83 | 1/86 | 0/86 |
| InfluenzaInfections and infestations | 0/30 | 0/32 | 0/30 | 0/29 | 1/83 | 0/86 | 0/86 |
| Head injuryInjury, poisoning and procedural complications | 0/30 | 0/32 | 0/30 | 0/29 | 1/83 | 0/86 | 0/86 |
| Event | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 |
|---|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 30/30 | 27/32 | 24/30 | 27/29 | 59/83 | 70/86 | 64/86 |
| Sleep deficitNervous system disorders | 24/30 | 18/32 | 13/30 | 18/29 | 43/83 | 45/86 | 38/86 |
| TendernessGeneral disorders | 23/30 | 23/32 | 19/30 | 22/29 | 48/83 | 53/86 | 49/86 |
| Increased need for sleepNervous system disorders | 22/30 | 24/32 | 21/30 | 22/29 | 42/83 | 48/86 | 48/86 |
| Decreased appetiteGeneral disorders | 17/30 | 11/32 | 11/30 | 13/29 | 33/83 | 30/86 | 33/86 |
| Injection site erythemaGeneral disorders | 13/30 | 7/32 | 10/30 | 15/29 | 34/83 | 28/86 | 38/86 |
| Injection site swellingGeneral disorders | 5/30 | 4/32 | 9/30 | 10/29 | 31/83 | 27/86 | 28/86 |
| InsomniaPsychiatric disorders | 6/30 | 1/32 | 2/30 | 0/29 | 0/83 | 0/86 | 0/86 |
| PyrexiaGeneral disorders | 1/30 | 1/32 | 1/30 | 1/29 | 9/83 | 16/86 | 10/86 |
| IrritabilityPsychiatric disorders | 4/30 | 1/32 | 4/30 | 2/29 | 0/83 | 1/86 | 0/86 |
Analysis was performed on the Safety Analysis Set (SAF) which includes all the participants who were randomized and received at least 1 study vaccination with either AFX3772 or PCV.
| Age, Continuous(Days) | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 | Total |
|---|---|---|---|---|---|---|---|---|
| Part 1 | 66.6 ± 6.83 | 64.6 ± 5.89 | 65.9 ± 13.98 | 65.7 ± 8.45 | — | — | — | 65.7 ± 9.20 |
| Part 2 | — | — | — | — | 65.7 ± 9.59 | 64.7 ± 8.60 | 65.2 ± 8.40 | 65.2 ± 8.85 |
| Sex/Gender, Customized(Participants) | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 | Total |
|---|---|---|---|---|---|---|---|---|
| Male | 16 | 12 | 15 | 14 | 43 | 40 | 46 | 186 |
| Female | 14 | 20 | 15 | 15 | 40 | 46 | 40 | 190 |
| Race/Ethnicity, Customized(Participants) | Part 1: AFX3772 1 µg | Part 1: AFX3772 2 µg | Part 1: AFX3772 5 µg | Part 1 Comparator: PCV13 | Part 2: AFX3772 2 µg | Part 2: AFX3772 5 µg | Part 2 Comparator: PCV20 | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 6 | 2 | 1 | 10 |
| Asian | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 1 | 1 | 2 | 0 | 11 | 9 | 21 | 45 |
| White or Caucasian | 23 | 27 | 23 | 25 | 53 | 64 | 52 | 267 |
| Mutiple | 2 | 2 | 4 | 3 | 8 | 6 | 5 | 30 |
| Other | 2 | 0 | 0 | 0 | 5 | 4 | 7 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Jun 2022 to primary completion in Sep 2025, 39 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 13-valent pneumococcal vaccine · Pneumococcal 20-Valent Conjugate Vaccine